CHAPTERS
- 0:00 – 5:29
Novo Nordisk’s Ozempic/Wegovy moment—and why it took 30 years
Ben and David frame Novo Nordisk as the company behind the breakout GLP-1 drugs Ozempic and Wegovy—and the surprising fact that it’s also historically been an insulin pure play. They lay out the staggering size of the diabetes/obesity markets and why semaglutide feels like it “appeared overnight,” despite decades of research and trials.
- •Novo’s revenue focus is overwhelmingly metabolic health (not a diversified pharma conglomerate)
- •Semaglutide’s roots: research began in the early 1990s; first trials in 2008; weight-loss efficacy trials completed in 2021
- •Market scale: diabetes and obesity prevalence and economic burden
- •Novo becomes Europe’s largest company amid GLP-1 demand
- •Pharma is complex—story starts before modern FDA/industry consolidation
- 5:29 – 12:55
Insulin is discovered in Toronto (1921) and the first supply-chain crisis begins
The hosts rewind to insulin’s discovery at the University of Toronto and explain why it was one of the most important medical breakthroughs ever. They describe the brutal reality of diabetes treatment pre-insulin, the early experimentation, and the immediate challenge: making enough insulin for patients who need it continuously.
- •Banting/Best/Macleod and the Nobel Prize controversy
- •Type 1 diabetes as a near-certain death sentence; “starvation diet” as the standard of care
- •Early insulin extraction from dog pancreases and first human injections
- •Insulin is life-extending, not curative—requires frequent ongoing dosing
- •The ethical firewall between academia and profit shaped early commercialization
- 12:55 – 16:33
Eli Lilly industrializes insulin—and brands it
To scale insulin beyond lab quantities, the University of Toronto licenses Eli Lilly. Lilly builds an animal-organ supply chain through slaughterhouses and develops manufacturing know-how, while the University insists on knowledge-sharing—except for one key asset Lilly keeps: the brand.
- •Toronto grants a one-year exclusive development license to Eli Lilly
- •Sourcing pancreases from cows/pigs becomes the practical path to scale
- •Lilly shares manufacturing advances back to Toronto (IP commons-style)
- •Lilly retains branding rights—early recognition of trust/quality signals
- •Insulin production becomes the foundation of Lilly’s modern pharma leadership
- 16:33 – 32:10
August Krogh’s personal stake: diabetes diagnosis leads to Nordisk’s founding
Novo Nordisk’s origin story begins with Danish Nobel laureate August Krogh, whose wife Marie is diagnosed with diabetes. A delayed US lecture tour connects Krogh to Toronto’s insulin work, enabling him—along with physician H.C. Hagedorn—to bring insulin production to Denmark and secure Scandinavian rights.
- •August Krogh (animal biologist) nominates Banting/Macleod for the Nobel Prize
- •Marie Krogh’s diagnosis and the role of endocrinologist H.C. Hagedorn
- •Harvard/Yale lecture tour leads to learning about Toronto insulin
- •Toronto’s Insulin Committee grants Scandinavian rights (even though Denmark can’t patent drugs)
- •First insulin extraction in Denmark using local animal pancreases
- 32:10 – 37:27
A foundation-owned insulin maker is born: Nordisk’s unusual governance model
To commercialize insulin ethically and at scale, the founders create a dual structure: an operating company controlled by a foundation. The mission splits access and profit: sell at cost in Scandinavia, use export profits to fund diabetes research—an architecture that will later save the company from being sold.
- •Creation of a foundation-controlled operating entity (Nordisk Insulin)
- •At-cost insulin in Scandinavia; market-price exports to fund research grants
- •Insulin brand ‘Insulin Leo’ and early European demand surge
- •This governance model persists into today’s publicly traded Novo Nordisk
- •Foundation control later becomes decisive in major strategic inflection points
- 37:27 – 47:13
The split that created Novo: a fired factory leader starts a bitter rival
Two early employees—the Pedersen brothers—clash with Hagedorn over operational control. After Thorvald is fired and Krogh backs Hagedorn, the brothers found a competing insulin company down the street, launching decades of intense competition that accelerates innovation.
- •Harald and Thorvald Pedersen: engineering + factory ops strengths
- •Power struggle: Hagedorn vs. Thorvald over who runs production
- •Drug patent limits in Denmark enable a fast competitive entry
- •Novo is born from a personal feud and a ‘we’ll show you’ moment
- •Head-to-head rivalry drives pace and ambition in insulin innovation
- 47:13 – 56:03
Insulin innovation arms race—and World War II reshapes the winners
Novo and Nordisk trade product breakthroughs and lawsuits (including a Danish Supreme Court case led by Hagedorn). WWII then flips fortunes: Nordisk’s licensing revenue collapses under Nazi occupation, while Novo scales as the sanctioned supplier across occupied Europe—an ethically complex but business-defining era.
- •Novo’s shelf-stable liquid insulin beats tablets on convenience and price
- •Nordisk’s NPH (Neutral Protamine Hagedorn) extends duration and reduces injections
- •Patent workarounds, lawsuits, and a Supreme Court showdown
- •Nazi occupation cuts Nordisk off from Allied licensing payments; Novo scales production
- •Post-war: Danish state requires repayment of wartime profits
- 56:03 – 1:08:32
Post-war growth, diversification, and the 1970s near-merger that didn’t happen
After the war, Novo becomes Europe’s insulin leader (Lente insulin; later ultra-pure MC insulin) and diversifies into industrial enzymes (Novozymes). A crash in enzymes strains capital, prompting merger talks—yet Nordisk’s ‘lumber CEO’ Henry Brennum rejects the deal and instead rebuilds Nordisk into a growing global competitor.
- •Novo’s Lente insulin and MC insulin raise efficacy/purity standards
- •Eli Lilly often licenses Danish innovations for the US market
- •Novo’s enzyme business adds diversification but creates capital intensity
- •Brennum rebuilds Nordisk: production capacity + global sales force + US push
- •1970s: Nordisk’s 30% CAGR growth revives the rival and shifts power balance
- 1:08:32 – 1:22:47
Biotech changes everything: Genentech, recombinant insulin, and the path to the 1989 merger
The 1980 Genentech–Eli Lilly partnership makes recombinant human insulin feasible and scalable, unlocking Type 2 insulin treatment and exploding demand. Novo’s attempt to ‘beat’ Lilly with chemically modified pig insulin flops, while Nordisk patiently scales—setting the stage for the eventual Novo–Nordisk merger as scale becomes mandatory in biotech manufacturing and go-to-market.
- •Type 2 diabetes explodes; animal-based insulin supply is the limiting factor
- •Genentech + Lilly produce recombinant human insulin—the first major biotech product
- •Novo’s chemically modified ‘human’ insulin attempt becomes a boondoggle (but fuels a US IPO)
- •Nordisk’s disciplined approach pays off; market shares converge by late 1980s
- •1989: Novo and Nordisk merge (operating companies + foundations) to compete at scale
- 1:22:47 – 1:31:57
Modern pharma go-to-market: PBMs, formularies, rebates, and why the US is uniquely complex
To explain why scale matters, the hosts map the US drug distribution and reimbursement stack—from manufacturer to wholesaler to pharmacy to insurer to PBM—with rebates and formularies distorting the ‘price’ patients see. They highlight PBM consolidation, vertical integration, and how these structures affect market access and bargaining power.
- •Supply chain: manufacturer → wholesaler (McKesson/Cardinal) → pharmacy → patient
- •PBMs negotiate rebates; list price vs net price becomes opaque
- •Three PBMs dominate: Express Scripts, CVS Caremark, OptumRx
- •Vertical integration: PBMs bundled with pharmacies and insurers
- •Rebates can reach extreme levels (e.g., claims of ~75% of insulin list price)
- 1:31:57 – 1:43:49
The foundation blocks a 2004 sale—then GLP-1 becomes the company’s future
After years of compounding, management tries to sell Novo Nordisk (Serono deal), but the foundation exercises its charter and rejects the merger. That decision preserves independence just as internal research—led by Lotte Bjerre Knudsen—nears a breakthrough in GLP-1 drugs that will redefine the company.
- •Novo Nordisk plans to merge into big pharma amid 1990s consolidation
- •2004 Serono sale attempt fails when foundation demands a ‘convincing business argument’
- •Foundation governance prevents a likely roll-up at a takeover premium
- •Lotte Bjerre Knudsen’s GLP-1 work is advancing inside the company
- •Counterfactual: without the structure, today’s GLP-1 story may not exist
- 1:43:49 – 2:27:18
Inventing GLP-1: liraglutide’s fatty-acid trick, lizard venom, and the long road to Ozempic/Wegovy
The episode dives into the science and product history of GLP-1 agonists: why native GLP-1 degrades in minutes, how liraglutide achieved a 13-hour half-life, and why Byetta (from Gila monster venom) hit first but with limitations. The arc culminates in semaglutide’s weekly dosing and ~15%+ weight-loss results that finally cross the ‘10% threshold’ and ignite global demand.
- •Native GLP-1 is metabolized in ~5 minutes—core drug-development barrier
- •Liraglutide’s fatty-acid attachment protects the molecule (albumin binding) to extend half-life
- •Byetta (2005) arrives first via Gila monster venom discovery; requires 2 injections/day
- •Victoza (2010) becomes a blockbuster; off-label weight-loss use accelerates demand
- •Semaglutide (Ozempic 2018; Wegovy 2021) brings weekly dosing and ~15%+ weight loss; supply constraints persist
- 2:27:18 – 2:44:51
GLP-1 economics and access: who pays, why insurers hesitate, and adherence challenges
Ben and David examine pricing, coverage, and incentives—especially in the US—where Medicare is legally barred from covering weight-loss drugs and private insurers face short time horizons. They also cover real-world frictions like side effects, discontinuation rates, and why demand may remain enormous even as payers try to slow adoption.
- •US sticker prices: Ozempic ~$1,000+/month; Wegovy ~$1,300+/month vs far lower abroad
- •Insurers’ short tenure with members undermines ROI for preventive obesity coverage
- •Medicare Part D prohibition on weight-loss coverage shapes the market debate
- •Adherence and discontinuation: side effects, supply shortages, and cost drive drop-off
- •Eli Lilly’s competitive entry (Mounjaro/Zepbound; tirzepatide) expands supply and intensifies innovation
- 2:44:51 – 3:45:25
Strategy teardown: Seven Powers, insulin’s collapse, and the broader healthcare value debate
The hosts apply the ‘Seven Powers’ lens—patents as cornered resources, manufacturing and go-to-market scale, switching costs, and surprising brand effects from Ozempic’s cultural virality. They then broaden to industry-level incentives: insulin profitability erodes via regulation/biosimilars, and the US healthcare system’s middlemen and misaligned time horizons complicate value creation vs capture.
- •Power sources: patents (cornered resource), scale in R&D/manufacturing/go-to-market, switching costs
- •Ozempic’s unusual pharma ‘brand power’ and word-of-mouth dynamics
- •Insulin business becomes less attractive: pricing backlash, caps, biosimilars, GLP-1 substitution
- •Playbook themes: extreme concentration, long-term R&D horizons, foundation-driven governance
- •Value capture debate: pharma risk-taking vs other healthcare profit pools; ROI and incentive alignment problems
